Gabelli Funds LLC Lowers Position in DaVita Inc. $DVA

Gabelli Funds LLC lowered its stake in shares of DaVita Inc. (NYSE:DVA) by 42.8% during the first quarter, HoldingsChannel.com reports. The firm owned 13,107 shares of the company’s stock after selling 9,800 shares during the period. Gabelli Funds LLC’s holdings in DaVita were worth $2,014,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Root Financial Partners LLC grew its stake in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares during the period. Caitlin John LLC purchased a new position in shares of DaVita in the 4th quarter worth $34,000. Sankala Group LLC purchased a new position in shares of DaVita in the 4th quarter worth $39,000. Canada Pension Plan Investment Board acquired a new position in DaVita in the second quarter valued at $43,000. Finally, Kestra Advisory Services LLC purchased a new stake in DaVita during the fourth quarter valued at about $45,000. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE DVA opened at $240.59 on Thursday. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $244.49. The company has a market capitalization of $15.45 billion, a price-to-earnings ratio of 22.32, a PEG ratio of 0.78 and a beta of 0.88. The business has a 50-day moving average of $216.12 and a 200-day moving average of $171.76.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.33 by $0.54. The business had revenue of $3.42 billion for the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company’s revenue was up 6.0% on a year-over-year basis. During the same period last year, the business posted $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts expect that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on the company. Barclays upped their price target on DaVita from $194.00 to $218.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. TD Cowen increased their target price on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Truist Financial raised their price target on shares of DaVita from $205.00 to $250.00 and gave the company a “hold” rating in a report on Tuesday, July 14th. Finally, Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 6th. Two investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $216.50.

Insider Activity at DaVita

In other news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Kathleen Alyce Waters sold 15,405 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total transaction of $3,210,402.00. Following the transaction, the insider directly owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 1.90% of the stock is owned by company insiders.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.